The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Pre-Eclampsia*/diagnosis ; Pre-Eclampsia*/epidemiology; Placenta Growth Factor/*blood ; Vascular Endothelial Growth Factor Receptor-1/*blood; Biomarkers ; Feasibility Studies ; Female ; Humans ; Malaysia/epidemiology ; Male ; Mothers ; Predictive Value of Tests ; Pregnancy ; Pregnancy Outcome ; Prospective Studies ; Vascular Endothelial Growth Factor A

Background: Preeclampsia significantly contributes to maternal and perinatal morbidity and mortality. It is imperative to identify women at risk of developing preeclampsia in the effort to prevent adverse pregnancy outcomes through early intervention. Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) level changes are noticeable several weeks before the onset of preeclampsia and its related complications. This study evaluated the feasibility of the sFlt-1/PlGF biomarker ratio in predicting preeclampsia and adverse pregnancy outcomes using a single cut-off point of >38.
Methods: This is a prospective cohort study conducted at a single tertiary centre, in an urban setting in Kuala Lumpur, Malaysia, between December 2019 and April 2021. A total of 140 medium to high risk mothers with singleton pregnancies were recruited at ≥20 weeks' gestation. sFlt-1/PlGF ratio was measured and the participant monitored according to a research algorithm until delivery. The primary outcome measure was incidence of preeclampsia and the secondary outcome measure was incidence of other adverse pregnancy outcomes.
Results: The overall incidence of preeclampsia was 20.7% (29/140). The mean sFlt-1/PlGF ratio was significantly higher in preeclampsia (73.58 ± 93.49) compared to no preeclampsia (13.41 ± 21.63) (p = 0.002). The risk of preeclampsia (adjusted OR 28.996; 95% CI 7.920-106.164; p<0.001) and low Apgar score (adjusted OR 17.387; 95% CI 3.069-98.517; p = 0.028) were significantly higher among women with sFlt-1/PlGF ratio >38 compared with sFLT-1/PlGF ratio ≤38. The area under the receiver-operator characteristic curve (AUC) for a combined approach (maternal clinical characteristics and biomarker) was 86.9% (p<0.001, 95% CI 78.7-95.0) compared with AUC biomarker alone, which was 74.8% (p<0.001, 95% CI 63.3-86.3) in predicting preeclampsia. The test sensitivity(SEN) was 58.6%, specificity (SPEC) 91%,positive predictive value (PPV) 63% and negative predictive value (NPV) 89.3% for prediction of preeclampsia. For predicting a low Apgar score at 5 minutes, the SEN was 84.6%, SPEC 87.4%, PPV 40.7%, and NPV 98.2%; low birth weight with SEN 52.6%,SPEC 86.0%, PPV 37.0%, NPV 92.0%; premature delivery with SEN 48.5%, SPEC 89.5%, PPV 59.3%, NPV 84.7% and NICU admission with SEN 50.0%, SPEC 85.8%, PPV 37.0% and NPV 91.2%.
Conclusions: It is feasible to use single cut-off point of >38 ratio of the biomarkers sFlt-1/PlGF in combination with other parameters (maternal clinical characteristics) in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers without restricting outcome measurement period to 1 and 4 weeks in a single urban tertiary centre in Kuala Lumpur, Malaysia.
Competing Interests: Funding This research received funding through the Fundamental Grant (FF-2019-371) and Matching Grant (FF-2019-371/1) from Universiti Kebangsaan Malaysia. Conflict of Interest Provision of Elecsys sFlt-1/PlGF and PreciControl Multimaker test kits from Roche Diagnostics International Ltd is acknowledged. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Am J Obstet Gynecol. 2010 Feb;202(2):161.e1-161.e11. (PMID: 19850276)
J Hypertens. 2008 Feb;26(2):295-302. (PMID: 18192844)
J Am Soc Nephrol. 2010 Oct;21(10):1691-701. (PMID: 20688931)
PLoS One. 2015 Aug 13;10(8):e0135301. (PMID: 26270471)
BJOG. 2020 Dec;127(13):1590-1597. (PMID: 32701207)
Hypertension. 2019 Jul;74(1):164-172. (PMID: 31188674)
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9267-71. (PMID: 1924389)
Circ Res. 2006 Sep 29;99(7):715-22. (PMID: 16946136)
Hypertens Res. 2021 Jul;44(7):822-829. (PMID: 33594274)
Hypertension. 2018 Jul;72(1):24-43. (PMID: 29899139)
Ultrasound Obstet Gynecol. 2016 Mar;47(3):324-31. (PMID: 26387758)
J Clin Invest. 2003 Mar;111(5):649-58. (PMID: 12618519)
Psychol Med. 1991 Nov;21(4):999-1012. (PMID: 1780412)
Microcirculation. 2018 Dec 16;:e12522. (PMID: 30556222)
Am J Obstet Gynecol. 2016 Jan;214(1):103.e1-103.e12. (PMID: 26297382)
Pregnancy Hypertens. 2014 Apr;4(2):97-104. (PMID: 26104417)
Hypertens Res. 2017 Mar;40(3):213-220. (PMID: 27682655)
Best Pract Res Clin Obstet Gynaecol. 2016 Oct;36:83-102. (PMID: 27531686)
Hypertension. 2017 Mar;69(3):457-468. (PMID: 28115513)
Hypertension. 2013 May;61(5):932-42. (PMID: 23460278)
N Engl J Med. 2004 Feb 12;350(7):672-83. (PMID: 14764923)
BMJ. 2011 Apr 07;342:d1875. (PMID: 21474517)
BJOG. 2014 Mar;121 Suppl 1:14-24. (PMID: 24641531)
Ann Lab Med. 2018 Mar;38(2):95-101. (PMID: 29214752)
PLoS One. 2019 Jul 3;14(7):e0218669. (PMID: 31269052)
Ultrasound Obstet Gynecol. 2017 Jun;49(6):756-760. (PMID: 28295782)
Thromb Res. 2011 Feb;127 Suppl 3:S72-5. (PMID: 21262447)
Geburtshilfe Frauenheilkd. 2015 Sep;75(9):900-914. (PMID: 28435172)
J Obstet Gynaecol Res. 2009 Oct;35(5):855-63. (PMID: 20149032)
BMC Pregnancy Childbirth. 2003 Oct 3;3(1):6. (PMID: 14525621)
Ultrasound Obstet Gynecol. 2021 Nov;58(5):688-697. (PMID: 32851709)
Exp Mol Med. 2012 Jan 31;44(1):1-9. (PMID: 22228176)
Front Physiol. 2018 Jul 25;9:973. (PMID: 30090069)
Nat Med. 2006 Jun;12(6):642-9. (PMID: 16751767)
Dis Markers. 2019 Aug 14;2019:4096847. (PMID: 31485276)
Pregnancy Hypertens. 2013 Apr;3(2):124-32. (PMID: 26105949)
PLoS One. 2012;7(7):e40589. (PMID: 22808199)
Ultrasound Obstet Gynecol. 2018 Jun;51(6):743-750. (PMID: 29536574)
Expert Rev Obstet Gynecol. 2010 Sep 1;5(5):557-566. (PMID: 21170149)
Epidemiology. 1996 May;7(3):245-9. (PMID: 8728436)
Ultrasound Obstet Gynecol. 2015 Mar;45(3):241-6. (PMID: 25736847)
Hypertension. 2016 Apr;67(4):740-7. (PMID: 26831193)
Malays J Pathol. 2014 Apr;36(1):19-26. (PMID: 24763231)
Best Pract Res Clin Obstet Gynaecol. 2011 Aug;25(4):391-403. (PMID: 21333604)
J Clin Diagn Res. 2014 Apr;8(4):BE01-4. (PMID: 24959436)
BMC Health Serv Res. 2018 Aug 6;18(1):603. (PMID: 30081904)
N Engl J Med. 2016 Jan 7;374(1):13-22. (PMID: 26735990)
Am J Obstet Gynecol. 2019 Feb;220(2):199.e1-199.e13. (PMID: 30447210)
Hypertension. 2020 Apr;75(4):918-926. (PMID: 32063058)
Am J Obstet Gynecol. 2003 Jan;188(1):177-82. (PMID: 12548214)
Scand J Work Environ Health. 2007 Aug;33(4):304-17. (PMID: 17717623)
Endocr Rev. 2004 Aug;25(4):581-611. (PMID: 15294883)
BMC Pregnancy Childbirth. 2014 Aug 28;14:292. (PMID: 25169665)
J Biol Chem. 2011 Nov 18;286(46):39933-44. (PMID: 21937443)
PLoS One. 2011;6(9):e24872. (PMID: 21969865)
Hypertens Res. 2021 Jul;44(7):813-821. (PMID: 33727707)
BJOG. 2017 Jul;124(8):1246-1253. (PMID: 27770512)
PLoS One. 2016 May 31;11(5):e0156013. (PMID: 27243815)

0 (Biomarkers)
0 (PGF protein, human)
0 (Vascular Endothelial Growth Factor A)
144589-93-5 (Placenta Growth Factor)
EC 2.7.10.1 (FLT1 protein, human)
EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)

Date Created: 20220311 Date Completed: 20220503 Latest Revision: 20220531

20240513

PMC8916650

10.1371/journal.pone.0265080

35275947